Placebo News and Research

RSS

FDA issues complete response letter to Takeda’s NDAs for type 2 diabetes investigational therapies

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. today announced that the company received a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone.

26 Apr 2012

Botox effect modest in migraine prevention: Study

Botox injections have been used in prevention of migraines but new research shows that its effect is only modest. Among chronic sufferers who had at least 15 migraines a month, the treatment prevented, on average, about two headaches a month. Botox was no more effective than some of the most widely prescribed drugs used for migraines when the treatments were compared.

25 Apr 2012

Vitamin D supplementation in winter can help lower blood pressure in hypertensive patients

A new study, presented at the European Society of Hypertension meeting in London, shows that vitamin D supplementation in winter can help lower blood pressure in patients with hypertension.

25 Apr 2012

S-equol effective in reducing menopausal hot flashes, muscle and joint pain among U.S. women

A dose of 10 milligrams (mg) daily of S-equol delivered via a newly developed fermented soy germ-based nutritional supplement is as effective as a standard dose of soy isoflavones at reducing hot flash frequency significantly and is even more effective for relieving muscle and joint pain, according to a peer-reviewed study in US postmenopausal women published in the June Journal of Women's Health, available now as a Fast Track article online ahead of print.

25 Apr 2012

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Biogen Idec announces positive data from oral BG-12 second Phase 3 trial on RRMS

Today Biogen Idec announced that detailed positive data from CONFIRM, the second Phase 3 clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS), will be presented in three platform presentations at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans.

25 Apr 2012

Gabapentin drug helps people to quit cannabis

Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana.

24 Apr 2012

R-Tech Ueno completes RK-023 phase I study on hypotrichosis of the eyelashes

R-Tech Ueno is pleased to announce the completion of a phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes.

24 Apr 2012

Women & Infants named lead center in 14-site study of cytomegalovirus

Women & Infants Hospital of Rhode Island, through its participation in the Maternal-Fetal Medicine Units Network, has been named the lead center in a 14-site, $25 million study of cytomegalovirus (CMV), the most common infection during pregnancy.

24 Apr 2012

Autism symptoms treatment using antidepressant SSRIs may not be effective: Review

According to a new review of published and unpublished research, the belief that certain antidepressants can help to treat repetitive behaviors in kids with autism may be based on incomplete information.

24 Apr 2012

Botox injections may improve frequency of chronic daily and migraine headaches

Although botulinum toxin A injections are U.S. Food and Drug Administration approved for preventive treatment for chronic migraines, a review and analysis of previous studies finds a small to modest benefit for patients with chronic migraine headaches and chronic daily headaches, although botox injections were not associated with greater benefit than placebo for preventing episodic migraine or chronic tension-type headaches, according to an article in the April 25 issue of JAMA.

24 Apr 2012

Asubio commences SUN13837 Phase 2 clinical trial for acute spinal cord injury

Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury.

23 Apr 2012

MicuRx completes MRX-I Phase 1 trial on MRSA and VRE infection

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate.

23 Apr 2012

Estrone provides anti-inflammatory and antioxidant capabilities after TBI

With more than 1.7 million people sustaining a traumatic brain injury each year, the need to identify processes to limit inflammation and subsequent damage is critical. Approximately 275,000 people are hospitalized annually with traumatic brain injury, leaving 85,000 with long-term disabilities and taking the lives of more than 50,000. More than 5 million people live with disabilities caused by traumatic brain injuries, often the result of car accidents and falls. Direct and indirect costs exceed $75 billion.

23 Apr 2012

New drug can prevent exacerbations of asthma due to common cold: Trial report

For the tens of thousands of asthma sufferers in the UK there is a “breakthrough” drug that reduces complications caused by the common cold, it is claimed.

22 Apr 2012

Large doses of vitamin C may moderately reduce blood pressure

Taking large doses of vitamin C may moderately reduce blood pressure, according to an analysis of years of research by Johns Hopkins scientists. But the researchers stopped short of suggesting people load up on supplements.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

Researchers revisit Charcot's vibration therapy for Parkinson's disease

In the 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a "vibration chair," to relieve symptoms of Parkinson's disease. Charcot reported improvements in his patients, but he died shortly thereafter and a more complete evaluation of the therapy was never conducted.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

Interferon beta-1a shows promise against MS

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

20 Apr 2012